Photopsia and visual loss in a patient with lung cancer

Case

A 68-year-old Caucasian male with a history of lung carcinoma with metastasis to bone and lymph nodes, treated with 1.5 months of checkpoint inhibitor (CPI) pembrolizumab (antiprogrammed cell death protein-1 antibody), noted photopsia and decreased visual acuity in the left eye (OS) over 2 months. On examination, visual acuity was 20/25 in the right eye (OD) and 20/80 OS. Fundus evaluation revealed a small amount of subretinal fluid (SRF) OS. The right eye was unremarkable.

What is your next step?

A. Apply plaque radiotherapy
B. Perform fine needle aspiration biopsy
C. Apply photodynamic therapy
D. Continue pembrolizumab

Findings

Fundoscopic examination OS revealed an ill-defined, juxtapapillary, amelanotic choroidal mass with surrounding SRF involving the macula [Fig. 1a]. The lesion demonstrated indiscrete margins, measuring approximately 10 mm in diameter and 2.2 mm in ultrasonographic thickness [Fig. 1b]. By optical coherence tomography, the choroid was thickened and demonstrated a “lumpy, bumpy” surface configuration, suggestive of choroidal metastasis [Fig. 1c]. These features were suggestive of a partial response to pembrolizumab. The right eye was normal.

Figure 1: A 68-year-old Caucasian male presented with flashes and decreased vision in the left eye and was found to have (a) an ill-defined choroidal mass on fundoscopy of the left eye. (b) B scan ultrasonography of the left eye revealed a small amount of subretinal fluid inferiorly. (c) Optical coherence tomography revealed thickening of the choroid and subretinal fluid beneath the fovea

Diagnosis: Choroidal metastasis OS
Correct answer: D

Discussion

Choroidal metastasis is a serious finding, associated with only 24% survival at 5 years.[1] The most common primary tumor sites include cancers of the breast (37%), lung (27%), kidney (4%), gastrointestinal tract (4%), and cutaneous melanoma (2%).[2] Metastases with best 1-year survival originate from lung carcinoma (92%), cutaneous melanoma (70%), and breast cancer (66%), while those with the poorest 1-year survival exhibit thyroid (35%), gastrointestinal (33%), and pancreatic (25% 6-month survival) origin.[3] Immunoinhibitory ligands are targeted by CPIs, upregulating the immune system to attack tumor. Ocular side effects include uveitis in 1% of patients; systemic side effects include lymphocytopenia and hepatitis.[5] Patients with systemic cancer and new ocular symptoms should have detailed ocular evaluation to determine the cause, such as medication-related, paraneoplastic syndrome, or metastatic disease.[6]

Declaraton of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References


Eric Shiuey, Sara E Lally, Carol L Shields

Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, United States

Correspondence to: Dr. Carol L Shields,

840 Walnut Street, Suite 1440, Philadelphia, PA 19107-5109, USA.

E-mail: carolshields@gmail.com

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

TIME IS OF THE ESSENCE

Keeler’s MIO – a revolution in Fundus Imaging Technology for adult and paediatric patients, helping Ophthalmologists worldwide conduct fast and affordable retinal examination!

Non-contact & portable digital retinal exams
Saves time with KineXis Imager for fundus auto-capture
Share documentation securely for patient engagement, education and analysis

“In a busy out-patient environment, the visit led to quick diagnosis, clear explanation of the required treatment to the patient and urgent treatment. The diagnosis would have been difficult to explain to the patient without images of the eye, prolonging the appointment and potentially delaying treatment.”

Dr. N.R. Rangaraj
Premiere Eye Care, Chennai

Available in India
www.keelermio.com

Today patients across the world are avoiding essential eye treatment for fear of the on-going pandemic. Innovative telemedicine technology in the ophthalmic field, like MIO, helps ensure safety for both doctor and patient. Retinal treatment is important. #EyeCareCannotWait